FDA Clears Novocure’s Optune Pax for Locally Advanced Pancreatic Cancer, Its Second U.S. Approval
FDA approved Optune Pax for unresectable or borderline resectable locally advanced pancreatic cancer, marking Novocure’s second U.S. cancer indication after glioblastoma. The decision enables use of tumor treating fields therapy in a patient population with limited device-based treatment options.
1. FDA Approval Details
On February 11, FDA approved Novocure’s Optune Pax device for the treatment of unresectable or borderline resectable locally advanced pancreatic cancer, expanding the company’s tumor treating fields (TTFields) portfolio beyond glioblastoma.
2. Mechanism and Clinical Data
Optune Pax delivers low-intensity alternating electric fields to disrupt cancer cell division; approval was based on a pivotal Phase 2 trial demonstrating a manageable safety profile and a median overall survival improvement over historical controls.
3. Market Opportunity and Commercial Launch Plans
Pancreatic cancer accounts for roughly 64,000 new U.S. diagnoses annually, with locally advanced cases representing about 30%; Novocure plans a mid-2026 commercial launch leveraging its existing oncology distribution network and secured reimbursement coverage.
4. Future Pipeline and Expansion
Following its glioblastoma approval in 2011, Novocure is pursuing additional solid tumor indications with ongoing studies in ovarian and hepatic cancers, aiming to further broaden its TTFields therapy platform.